Video

Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer

Publish date: January 6, 2012

 

SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrozole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.

Recommended Reading

Fulvestrant Adds Punch to Anastrozole for HR+ Breast Cancer
Breast Cancer ICYMI
Imiquimod/Abraxane Combo Effective for Skin Mets
Breast Cancer ICYMI
Less Trastuzumab Cardiotoxicity in Beta-Blocker Users
Breast Cancer ICYMI
Pegfilgrastim Costly, Unnecessary in Some Breast Cancer Patients
Breast Cancer ICYMI
Adjuvant Ibandronate: No Gain in Early Breast Cancer
Breast Cancer ICYMI
Program Curbs Shoulder Morbidity Post Breast Cancer
Breast Cancer ICYMI
Cancer Death Rates Continue to Drop
Breast Cancer ICYMI
Do Bisphosphonates Reduce Cancer Risks?
Breast Cancer ICYMI
Community Oncology Podcast - Radiation in breast cancer
Breast Cancer ICYMI
Retrospective Study of Patients with Metastatic Triple-Negative Breast Cancer: Survival, Health Care Utilization, and Cost
Breast Cancer ICYMI